US2003147860A1PendingUtilityA1
Compositions and methods for forming and strengthening bone
Priority: Feb 7, 2002Filed: Feb 7, 2002Published: Aug 7, 2003
Est. expiryFeb 7, 2022(expired)· nominal 20-yr term from priority
Inventors:J. Alexander Marchosky
A61L 27/52A61L 27/20A61L 27/227A61K 38/1866A61K 31/728A61L 27/3608A61K 35/32A61L 27/54A61K 31/722A61K 31/734A61P 19/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions are provided which stimulate bone growth. Also provided are methods for utilizing the compositions for filling in bone defects, promoting rapid fusion of bone fractures, grafts, and bone-prostheses, and promoting strengthening of osteoporotic bones.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A composition comprising:
(a) one or more materials selected from the group consisting of fibroblast growth factors, vascular endothelial growth factors, endothelial cell growth factors, transforming growth factors, chitosan, bone, platelet derived endothelial growth factors, placental growth factors, angiogenin, interleukin-8, granulocyte colony-stimulating growth factor, and supernatant fluid from a culture of cells known to produce angiogenic factors; (b) a material comprising demineralized bone matrix, non-decalcified bone matrix, with or without hyaluronic acid; (c) a scaffolding material selected from the group consisting of cancellous bone, chitosan, chitosan-protein, and chitin-protein fibers; and (d) a gel material selected from the group consisting of chitosan, imidazolyl chitosan, methylpyrrolidinone chitosan, carbodiimide chitosan, glutaraldehyde chitosan, a mixture of alginate with chitosan or a chitosan derivative, alginate, hyaluronic acid, or a mixture of hyaluronic acid with chitosan or chitosan derivative.
2 . A composition comprising:
(a) one or more angiogenesis-stimulating materials; (b) one or more osteoinductive materials; (c) one or more scaffolding materials; and (d) one or more gel materials.
3 . A composition comprising:
(a) one or more angiogenesis-stimulating materials selected from the group consisting of fibroblast growth factors, vascular endothelial growth factors, endothelial cell growth factors, transforming growth factors, chitosan, bone, platelet derived endothelial growth factors, placental growth factors, angiogenin, interleukin-8, and granulocyte colony-stimulating growth factor; (b) an osteoinductive material comprising demineralized bone matrix, non-decalcified bone matrix, with or without hyaluronic acid; (c) a scaffolding material selected from the group consisting of cancellous bone, chitosan, chitosan-protein, and chitin-protein fibers; and (d) a gel material selected from the group consisting of chitosan, imidazolyl chitosan, methylpyrrolidinone chitosan, carbodiimide chitosan, glutaraldehyde chitosan, and a mixture of alginate with chitosan or a chitosan derivative.
4 . The composition of claim 1 , wherein one or more of the said materials is basic fibroblast growth factor, a vascular endothelial growth factor, platelet derived endothelial growth factor, bone, or supernatant fluid from a culture of cells known to produce angiogenic factors; another material of said composition is a mixture of demineralized bone matrix and non-decalcified bone matrix; the scaffolding material is cancellous bone; and the gel material is selected from the group consisting of chitosan, alginate, hyaluronic acid, a mixture of chitosan and alginate, or a mixture of hyaluronic acid and chitosan.
5 . The composition of claim 4 , wherein one or more of the said materials is basic fibroblast growth factor, platelet derived endothelial growth factor, or vascular endothelial growth factor and is present at 10 −6 to 30 mg/ml; the demineralized bone matrix is present at 5-30%; the non-decalcified bone matrix is present at 5-30%; the scaffolding material is cancellous bone milled to 0.1-1.5 mm in its longest diameter and is present at 10-40%; and the gel material is a 0.5-5% (w/v) concentration selected from the group consisting of chitosan, alginate, hyaluronic acid, a mixture of alginate with chitosan, present at 10-80%, or a mixture of hyaluronic acid and chitosan.
6 . The composition of claim 4 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10%; the cancellous bone is present at 10%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
7 . A composition of claim 6 , wherein said fibroblast growth factor is present at <1 mg/ml.
8 . A composition of claim 6 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
9 . The composition of claim 4 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 20%; the cancellous bone is present at 20%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
10 . A composition of claim 9 , wherein said fibroblast growth factor is present at <1 mg/ml.
11 . A composition of claim 9 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
12 . The composition of claim 4 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10%; the cancellous bone is present at 30%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
13 . A composition of claim 12 , wherein said fibroblast growth factor is present at <1 mg/ml.
14 . A composition of claim 12 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
15 . The composition of claim 4 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10-15% (w/w); the cancellous bone is present at 15-25% (w/w); and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
16 . A composition of claim 15 , wherein said fibroblast growth factor is present at <1 mg/ml.
17 . A composition of claim 15 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
18 . The composition of claim 2 , wherein one or more of the angiogenesis-stimulating materials is basic fibroblast growth factor, a vascular endothelial growth factor, platelet derived endothelial growth factor, bone, or supernatant fluid from a culture of cells known to produce angiogenic factors; the osteoinductive material of said composition is a mixture of demineralized bone matrix and non-decalcified bone matrix; the scaffolding material is cancellous bone; and the gel material is selected from the group consisting of alginate, chitosan, hyaluronic acid, a mixture of chitosan and alginate, or a mixture of hyaluronic acid and chitosan.
19 . The composition of claim 18 , wherein one or more of the said angiogenesis-stimulating materials is basic fibroblast growth factor, platelet derived endothelial growth factor, or vascular endothelial growth factor and is present at 10 −6 to 30 mg/ml; the demineralized bone matrix is present at 5-15%; the non-decalcified bone matrix is present at 5-15%; the scaffolding material is cancellous bone milled to 0.1-1.5 mm in its longest diameter and is present at 10-40%; and the gel material is a 2-5% (w/v) concentration selected from the group consisting of chitosan, alginate, hyaluronic acid, a mixture of alginate with chitosan, present at 35-80%, or a mixture of hyaluronic acid and chitosan, present at 35-80%.
20 . The composition of claim 18 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10%; the cancellous bone is present at 10%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
21 . A composition of claim 20 , wherein said fibroblast growth factor is present at <1 mg/ml.
22 . A composition of claim 20 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
23 . The composition of claim 18 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 20%; the cancellous bone is present at 20%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
24 . A composition of claim 23 , wherein said fibroblast growth factor is present at <1 mg/ml.
25 . A composition of claim 23 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
26 . The composition of claim 18 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10%; the cancellous bone is present at 30%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
27 . A composition of claim 26 , wherein said fibroblast growth factor is present at <1 mg/ml.
28 . A composition of claim 26 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
29 . The composition of claim 18 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10-15% (w/w); the cancellous bone is present at 15-25% (w/w); and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
30 . A composition of claim 29 , wherein said fibroblast growth factor is present at <1 mg/ml.
31 . A composition of claim 29 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
32 . The composition of claim 3 , wherein one or more of the angiogenesis-stimulating materials is basic fibroblast growth factor, a vascular endothelial growth factor, platelet derived endothelial growth factor, bone, or supernatant fluid from a culture of cells known to produce angiogenic factors; the osteoinductive material of said composition is a mixture of demineralized bone matrix and non-decalcified bone matrix; the scaffolding material is cancellous bone; and the gel material is selected from the group consisting of alginate, chitosan, or a mixture of chitosan and alginate.
33 . The composition of claim 32 , wherein one or more of the said angiogenesis-stimulating materials is basic fibroblast growth factor, platelet derived endothelial growth factor, or vascular endothelial growth factor and is present at 10 −6 to 30 mg/ml; the demineralized bone matrix is present at 5-15%; the non-decalcified bone matrix is present at 5-15%; the scaffolding material is cancellous bone milled to 0.1-1.5 mm in its longest diameter and is present at 10-40%; and the gel material is a 2-5% (w/v) concentration selected from the group consisting of chitosan, alginate, or a mixture of alginate with chitosan, present at 35-80%.
34 . The composition of claim 32 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10%; the cancellous bone is present at 10%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
35 . A composition of claim 34 , wherein said fibroblast growth factor is present at <1 mg/ml.
36 . A composition of claim 34 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
37 . The composition of claim 32 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 20%; the cancellous bone is present at 20%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
38 . A composition of claim 37 , wherein said fibroblast growth factor is present at <1 mg/ml.
39 . A composition of claim 37 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
40 . The composition of claim 32 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10%; the cancellous bone is present at 30%; and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
41 . A composition of claim 40 , wherein said fibroblast growth factor is present at <1 mg/ml.
42 . A composition of claim 40 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
43 . The composition of claim 32 , wherein one or more of the said materials is an effective amount of fibroblast growth factors or vascular endothelial growth factors; the demineralized bone matrix is present at 10-15% (w/w); the cancellous bone is present at 15-25% (w/w); and the gel material is a 3% (w/v) concentration of alginate, or a mixture of alginate with chitosan.
44 . A composition of claim 43 , wherein said fibroblast growth factor is present at <1 mg/ml.
45 . A composition of claim 43 , wherein said vascular endothelial growth factors are present at <1 mg/ml.
46 . A composition for promoting the growth and strengthening of bone comprising a mixture of a chitosan or chitosan derivative, cancellous bone, and demineralized bone matrix.
47 . A composition of claim 46 , wherein said composition comprises demineralized bone matrix is present at 10%; the cancellous bone is present at 10%; and the gel material is a 3% (w/v)of chitosan or chitosan derivative.
48 . A composition of claim 46 , wherein said composition comprises demineralized bone matrix is present at 20%; the cancellous bone is present at 20%; and the gel material is a 3% (w/v)of chitosan or chitosan derivative.
49 . A composition of claim 46 , wherein said composition comprises demineralized bone matrix is present at 10%; the cancellous bone is present at 30%; and the gel material is a 3% (w/v)of chitosan or chitosan derivative.
50 . A composition for promoting the growth and strengthening of bone comprising a mixture of alginate, calcium, cancellous bone, and demineralized bone matrix.
51 . A composition of claim 50 , wherein said composition comprises demineralized bone matrix is present at 10%; the cancellous bone is present at 30%; and the gel material is a 3% (w/v) of alginate with or without calcium.
52 . A composition of claim 50 , wherein said composition comprises demineralized bone matrix is present at 20%; the cancellous bone is present at 20%; and the gel material is a 3% (w/v)of alginate with or without calcium.
53 . A composition of claim 50 , wherein said composition comprises demineralized bone matrix is present at 10%; the cancellous bone is present at 10%; and the gel material is a 3% (w/v)of alginate with or without calcium.
54 . A composition for promoting the growth and strengthening of bone comprising a mixture of chitosan or chitosan derivative, alginate, cancellous bone, and demineralized bone matrix.
55 . A composition of claim 54 , wherein said composition comprises demineralized bone matrix is present at 20% (w/w); the cancellous bone is present at 12% (w/w); and the gel material is 0.5% (w/w) alginate, 0.3% (w/w) chitosan.
56 . A composition for promoting the growth and strengthening of bone comprising a mixture of hyaluronic acid, cancellous bone, and demineralized bone matrix.
57 . A method of inducing bone formation in a vertebrate comprising applying a composition selected from the group consisting of the compositions of claims 1 - 56 to a site in the vertebrate where bone formation is desired.
58 . The method of claim 57 , wherein the site is the junction of an allograft or autograft and a bone.
59 . The method of claim 57 , wherein the site is the junction of a bone and a bone prosthesis.
60 . The method of claim 57 , wherein the site is a fracture.
61 . A method of filling a bone defect comprising filling the bone defect with a rigid material consisting essentially of chitin or chitosan.
62 . The method of claim 61 , wherein the bone defect is a cylindrical disconnected bone and the rigid material is a hollow tube filled with a chitosan solution.
63 . The method of claim 61 , wherein the bone defect is a spinal disc and the rigid material is a spinal prosthesis.
64 . The method of claim 61 , wherein the rigid material comprises chitin or chitosan cross-linked with glutaraldehyde, carbodiimide, lysine, or vinyl.Join the waitlist — get patent alerts
Track US2003147860A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.